This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Levin points out that the Dor Yesharim program is characterized by community member consultation and careful tailoring. This is distinct from the genetic disease screening advertisements for the Jewish community we cited as problematic. The advertisements we observed for other testing programs appeared in a national Jewish magazine and a regional Jewish community newspaper. While narrowly applied targeting has value, broader community targeting in marketing raises concerns.

The first relates to the bundling of tests for heterogeneous conditions without options to decline specific tests. Tay Sachs disease, cystic fibrosis, and Gaucher disease, among 8 of the "Jewish genetic conditions" described in the referenced advertisement, are clinically dissimilar, leading to different psychosocial implications to consider in reproductive decision making. With some panels, it might not be possible to refuse testing for a particular condition. There may even be financial disincentives to do so if the test package costs . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Direct-to-Consumer Advertising of Genetic Testing
Mark Levin
JAMA. 2003;289(1):45-46.
EXTRACT | FULL TEXT